These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31641413)

  • 1. Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac
    Sidgiddi S; Allenby K; Okumu F; Gautam A
    J Clin Aesthet Dermatol; 2019 Sep; 12(9):16-24. PubMed ID: 31641413
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin.
    Yu Z; Sefton J; Lew-Kaya D; Walker P; Yu D; Tang-Liu DD
    Clin Pharmacokinet; 2003; 42(10):921-9. PubMed ID: 12885265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
    Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
    J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris.
    Jarratt M; Werner CP; Alió Saenz AB
    Clin Drug Investig; 2013 Apr; 33(4):283-9. PubMed ID: 23456673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
    Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
    Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II
    Baldwin HE; Green LJ; Kircik L; Guenin EP; Forest AL; Pillai R
    J Clin Aesthet Dermatol; 2021 Apr; 14(4):E53-E60. PubMed ID: 34055190
    [No Abstract]   [Full Text] [Related]  

  • 7. Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies.
    Draelos ZD
    J Dermatolog Treat; 2023 Dec; 34(1):2166346. PubMed ID: 36622889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
    Tang-Liu DD; Matsumoto RM; Usansky JI
    Clin Pharmacokinet; 1999 Oct; 37(4):273-87. PubMed ID: 10554045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
    Yu Z; Yu D; Walker PS; Tang-Liu DD
    Clin Pharmacokinet; 2004; 43(10):673-84. PubMed ID: 15244497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Tape-Stripping Liquid Chromatography-Mass Spectrometry Method for Evaluating Skin Deposition of Topical Tazarotene.
    Draelos ZD; Draelos MM
    J Drugs Dermatol; 2021 Oct; 20(10):1105-1111. PubMed ID: 34636513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.
    Del Rosso JQ; Kircik L; Lin T; Pillai R
    J Clin Aesthet Dermatol; 2019 Jan; 12(1):11-15. PubMed ID: 30881571
    [No Abstract]   [Full Text] [Related]  

  • 12. In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream.
    Draelos Z; Tanghetti E; Werschler W; Kircik L; Angel A; Lagmay E; Guenin E
    J Drugs Dermatol; 2022 Mar; 21(3):250-257. PubMed ID: 35254756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.
    Pariser D; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s18-23. PubMed ID: 18575222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial.
    Phillips TJ; Gottlieb AB; Leyden JJ; Lowe NJ; Lew-Kaya DA; Sefton J; Walker PS; Gibson JR;
    Arch Dermatol; 2002 Nov; 138(11):1486-93. PubMed ID: 12437455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
    Tanghetti EA; Stein Gold L; Del Rosso JQ; Lin T; Angel A; Pillai R
    J Dermatolog Treat; 2021 Jun; 32(4):391-398. PubMed ID: 31522563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tazarotene 0.045% Lotion: A Novel Retinoid Formulation.
    Mohney LA; Singh R; Feldman SR
    Ann Pharmacother; 2022 Oct; 56(10):1174-1180. PubMed ID: 35112585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne.
    Tan J; Draelos ZD; Gooderham MJ; Alexis AF; Graber E; Keri J; Woolery-Lloyd HC; Harper JC; Cook-Bolden FE; Konda A; Tanghetti EA
    J Clin Aesthet Dermatol; 2023 Sep; 16(9):42-45. PubMed ID: 37720201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
    J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream.
    Bhatia ND; Pariser DM; Kircik L; Lin T; Harris S; Mathew L; Pillai R
    J Clin Aesthet Dermatol; 2018 Nov; 11(11):15-19. PubMed ID: 30588269
    [No Abstract]   [Full Text] [Related]  

  • 20. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
    Tanghetti E; Dhawan S; Torok H; Kircik L
    Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.